Valuation: Omeros Corporation

Market Cap 717M 628M 580M 541M 1.02B 67.81B 1.04B 6.98B 2.69B 33.45B 2.69B 2.63B 116B P/E 2026 *
30x
P/E 2027 * -35.4x
Enterprise Value 717M 628M 580M 541M 1.02B 67.81B 1.04B 6.98B 2.69B 33.45B 2.69B 2.63B 116B EV / Sales 2026 *
10.6x
EV / Sales 2027 * 5.01x
Free-Float
96.44%
Yield 2026 *
-
Yield 2027 * -
1 day+14.30%
1 week-4.07%
Current month-10.24%
1 month-10.24%
3 months+0.30%
6 months-40.19%
Current year-42.30%
1 week 7.39
Extreme 7.39
10.83
1 month 6.7
Extreme 6.7023
11
Current year 6.7
Extreme 6.7023
17.63
1 year 2.95
Extreme 2.95
17.65
3 years 0.92
Extreme 0.92
17.65
5 years 0.92
Extreme 0.92
17.65
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 1994-06-15
Director of Finance/CFO 62 2024-06-29
Chief Tech/Sci/R&D Officer 70 2019-10-31
Director TitleAgeSince
Chairman 67 1994-06-15
Director/Board Member 86 1994-12-31
Director/Board Member 72 1994-12-31
Date Insider Type Main position Quantity % Market Cap.
Jun. 17Free

Director

15,000 0.0207%
Jun. 17Free

Director

15,000 0.0207%
Jun. 17Free

Director

15,000 0.0207%
Change 5-day change 1-year change 3-year change Capi.($)
+14.30%-4.07%+209.69%+86.63% 717M
+1.96%-1.50%+70.46%+125.32% 55.78B
+6.76%+18.10%+91.66%+104.09% 55.66B
+3.33%+4.51%-11.68%-11.91% 23.84B
+1.32%+6.22%+5.28%+415.45% 22.7B
+7.03%+7.49%+39.66%-28.82% 16.12B
-0.89%+5.71%+24.30%+186.29% 13.64B
+9.96%+15.98%+157.65%+310.89% 14.8B
+2.85%+2.81%+75.32%+139.44% 12.16B
+6.17%+10.22%+163.15%+166.44% 11.85B
Average +5.28%+6.25%+82.55%+149.38% 22.73B
Weighted average by Cap. +4.23%+7.67%+66.78%+142.30%

Financials

2026 *2027 *
Net sales 67.83M 59.39M 54.83M 51.2M 96.39M 6.41B 98.58M 660M 255M 3.16B 255M 249M 10.98B 143M 125M 116M 108M 203M 13.53B 208M 1.39B 537M 6.67B 537M 526M 23.17B
Net income 21.23M 18.59M 17.16M 16.03M 30.17M 2.01B 30.86M 207M 79.74M 990M 79.74M 77.99M 3.44B -47.25M -41.37M -38.19M -35.67M -67.14M -4.47B -68.67M -460M -177M -2.2B -177M -174M -7.65B
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
26-06-29 $9.910 +14.30% 2,744,125
26-06-26 $8.670 -19.12% 10,918,913
26-06-25 $10.72 +1.32% 1,143,187
26-06-24 $10.58 +0.95% 1,174,601
26-06-23 $10.48 +1.45% 1,073,153
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
9.910USD
Average target price
33.00USD
Spread / Average Target
+233.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock